https://doi.org/10.18565/therapy.2022.9.107-113. EDN: GACOAM.

2. Koch H., van Bokhoven M.A., ter Riet G. et al. Demographic characteristics and quality of life of patients with unexplained complaints: A descriptive study in general practice. Qual Life Res. 2007; 16(9): 1483–89.

https://doi.org/10.1007/s11136-007-9252-y. PMID: 17899448. PMCID: PMC2039860.

3. Медведев В.Э. Психические расстройства репродуктивного цикла у женщин. Психиатрия. 2022; 20(2): 85–96. (Medvedev V.E. Mental disorders of the female reproductive cycle. Psikhiatriya = Psychiatry. 2022; 20(2): 85–96 (In Russ.)).

https://dx.doi.org/10.30629/2618-6667-2022-20-2-85-96. EDN: KDGDKR.

4. Wang X., Xu H., Jiang H. et al. The clinical features and outcomes of discharged coronavirus disease 2019 patients: A prospective cohort study. QJM. 2020; 113(9): 657–65.

https://doi.org/10.1093/qjmed/hcaa178. PMID: 32442308. PMCID: PMC7313792.

5. Herridge M.S., Moss M., Hough C.L. et al. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016; 42(5): 725–38.

https://doi.org/10.1007/s00134-016-4321-8. PMID: 27025938.

6. Morgul E., Bener A., Atak M. et al. COVID-19 pandemic and psychological fatigue in Turkey. Int J Soc Psychiatry. 2021; 67(2): 128–35.

https://doi.org/10.1177/0020764020941889. PMID: 32650681. PMCID: PMC7355205.

7. Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Scientific Reports. 2021; 11(1): 16144.

https://doi.org/10.1038/s41598-021-95565-8. PMID: 34373540. PMCID: PMC8352980.

8. Малявин А.Г., Горелов А.В., Васенина Е.Е. с соавт. Постинфекционная астения: современные подходы к терапии. Резолюция Экспертного совета Российского научного медицинского общества терапевтов и Национальной ассоциации специалистов по инфекционным болезням им. академика РАН В.И. Покровского. Профилактическая медицина. 2023; 26(9): 82–91. (Malyavin A.G., Gorelov A.V., Vasenina E.E. et al. Postinfectious asthenia: Modern approaches to therapy. The Russian Scientific Medical Society of Internal Medicine and The National Association of Infectious Diseases Specialists named after academician of the RAS V.I. Pokrovsky. Expert Council resolution. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine. 2023; 26(9): 82–91 (In Russ.)).

https://doi.org/10.17116/profmed20232609188. EDN: EAVKAU.

9. Петрова Л.В., Костенко Е.В., Энеева М.А. Астения в структуре постковидного синдрома: патогенез, клиника, диагностика и медицинская реабилитация. Доктор.Ру. 2021; 20(9): 36–42. (Petrova L.V., Kostenko E.V., Eneeva M.A. Asthenia and post-COVID syndrome: Pathogenesis, clinical presentations, diagnosis, and medical rehabilitation. Doctor.Ru. 2021; 20(9): 36–42 (In Russ.)).

https://doi.org/10.31550/1727-2378-2021-20-9-36-42. EDN: WFABSD.

10. Afari N., Buchwald D. Chronic fatigue syndrome: A review. Am J Psychiatry. 2003; 160(2): 221–36.

https://doi.org/10.1176/appi.ajp.160.2.221. PMID: 12562565.

11. Чутко Л.С., Сурушкина С.Ю. Астенические расстройства. История и современность. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(6): 131–136. (Chutko L.S., Surushkina S.Yu. Asthenic disorders. History and modernity. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120(6): 131–136 (In Russ.)).

https://doi.org/10.17116/jnevro2020120061131. EDN: SROTUY.

12. Overholser J., Beale E. Neurasthenia: Modern malady or historical relic? J Nerv Ment Dis. 2019; 207(9): 731–39.

https://doi.org/10.1097/nmd.0000000000000943. PMID: 31464984.

13. Fukuda K. The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med. 1994; 121(12): 953.

https://doi.org/10.7326/0003-4819-121-12-199412150-00009. PMID: 7978722.

14. Морозов П.В. Новое в лечение астении. Психиатрия и психофармакотерапия. 2005; 7(3): 154–159. (Morozov P.V. New in the treatment of asthenia. Psikhiatriya i psikhofarmakoterapiya = Psychiatry and psychopharmacotherapy. 2005; 7(3): 154–159 (In Russ.)). EDN: RDHXNV.

15. Воробьева А.А. Астенические состояния: эффективная и безопасная терапия. Русский медицинский журнал. 2009; 17(20): 1330–1333. (Vorobyova A.A. Asthenic conditions: Effective and safe therapy. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2009; 17(20): 1330–1333 (In Russ.)). EDN: PCZAJN.

16. Васенина Е.Е., Верюгина Н.И., Левин О.С. Постинфекционная астения и COVID-19. Терапия. 2021; 7(9): 114–125. (Vasenina E.E., Veryugina N.I., Levin O.S. Post-infectious asthenia and COVID-19. Terapiya = Therapy. 2021; 7(9): 114–125 (In Russ.)).

https://doi.org/10.18565/therapy.2021.9.125-136. EDN: CJBGRQ.

17. Harada K., Kohno K., Daira I. et al. Retention in the body of various o-acylthiamine disulfides and several properties of o-butyryl-thiamine disulfide. The Journal of Vitaminology. 1966; 12(3): 221–30.

https://doi.org/10.5925/jnsv1954.12.221. PMID: 5956793.

18. Balestreri R., Bertolini S., Barban G. et al. Effeto del disolfuro di bis-(isobutirrilossi-2-etile)-1-N-(amino-4-metil-2-pirimidil-5) metil formamido-2-propene-1-ile (Sulbutiamina) nelle sindromi neurasteniche e neuroasteniformi (Effect of bis-(isobutyryloxy-2-ethyl)-1-N-(amino-4-methyl-2-pyrimidyl-5) methyl formamido-2-propene-1-yl disulfide (Sulbutiamin) in neurasthenic and neuroastheniform syndromes). Arch Maragliano Patol Clin. 1979; 35: 19–34. Italian. PMID: 400511.

19. Kiew K.K., Wan Mohamad W.B., Ridzuan A., Mafauzy M. Effects of sulbutiamine on diabetic polyneuropathy: An open randomized controlled study in type 2 diabetics. Malays J Med Sci. 2002; 9(1): 21–27. PMID: 22969314. PMCID: PMC3436103.

20. Быков Ю.В., Беккер Р.А. Специфическое лечение астенических состояний: в фокусе сульбутиамин. Терапевтический архив. 2022; 94(5): 689–694. (Bykov Yu.V., Bekker R.A. On the specific treatment of asthenic states: Focus on sulbutiamine. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(5): 689–694 (In Russ.)).

https://doi.org/10.26442/00403660.2022.05.201533. EDN: BCSTXN.

21. (Du Boitesselin R., Hun M. Etude histochimique de l’impregnation des formations cerebrales apres administration de sulbutiamine. Synthese Medicale. 1985; 309: 11–12 (In French)).

22. Volvert M.L., Seyen S., Piette M. et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 2008; 8: 10.

https://doi.org/10.1186/1471-2210-8-10. PMID: 18549472. PMCID: PMC2435522.

23. Micheau J., Durkin T.P., Destrade C. et al. Chronic administration of sulbutiamine improves long term memory formation in mice: Possible cholinergic mediation. Pharmacol Biochem Behav. 1985; 2(23): 195–98.

https://doi.org/10.1016/0091-3057(85)90555-6. PMID: 4059305.

24. Михайлова Н.М. Применение Энериона для лечения астенических расстройств в психогериатрической практике. Психиатрия. 2004; (4): 65–67. (Mikhailova N.M. Use of Enerion for the treatment of asthenic disorders in psychogeriatric practice. Psikhiatriya = Psychiatry. 2004; (4): 65–67 (In Russ.)). EDN: PVPEMR.

25. Trovero F., Gobbi M., Weil-Fuggaza J. et al. Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain. Neurosci Lett. 2000; 292(1): 49–53.

https://doi.org/10.1016/s0304-3940(00)01420-8. PMID: 10996447.

26. Meltzer L.T., Christoffersen C.L., Serpa K.A. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev. 1997; 21(4): 511–18.

https://doi.org/10.1016/s0149-7634(96)00030-9. PMID: 9195610.

27. Stahl S.M. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press. 2013: 626 pp. ISBN: 978-1107686465.

28. Starling-Soares B., Carrera-Bastos P., Bettendorff L. Role of the synthetic B1 vitamin sulbutiamine on health. J Nutr Metab. 2020; 2020: 9349063.

https://doi.org/10.1155/2020/9349063. PMID: 32399290. PMCID: PMC7210561.

29. Kiew K.K., Wan Mohamad W.B., Ridzuan A., Mafauzy M. Effects of sulbutiamine on diabetic polyneuropathy: An open randomised controlled study in type 2 diabetics. Malays J Med Sci. 2002; 9(1): 21–27. PMID: 22969314. PMCID: PMC3436103.

30. Balzamo E., Vuillon-Cacciuttolo G. Facilitation of a state of wakefulness by semi-chronic treatment with sulbutiamin (Arcalion) in Macaca mulatta. Rev Electroencephalogr Neurophysiol Clin. 1982; 4(12): 373–78.

https://doi.org/10.1016/s0370-4475(82)80029-4. PMID: 7170385.

31. Attademo L., Bernardini F. Are dopamine and serotonin involved in COVID-19 pathophysiology? Eur J Psychiatry. 2021; 35(1): 62–63.

https://doi.org/10.1016/j.ejpsy.2020.10.004. PMID: 33162632. PMCID: PMC7598536.

32. Вейн А.М., Густов А.В., Руднев В.А. с соавт. Энерион в лечении астении в рамках психовегетативного синдрома (мультицентровое исследование). Лечение нервных болезней. 2003; 4(3): 43–49. (Vein A.M., Gustov A.V., Rudnev V.A. et al. Enerion in the treatment of asthenia within the framework of psychovegetative syndrome (multicenter study). Lecheniye nervnykh bolezney = Treatment of Nervous Diseases. 2003; 4(3): 43–49 (In Russ.)). EDN: TVEKNR.

33. Вейн А.М., Федотова А.В., Гордеев С.А. Энерион – эффективное и безопасное средство для лечения астении у больных с психовегетативным синдромом. РМЖ. 2004; 12(10): 631–633. (Vein A.M., Fedotova A.V., Gordeev S.A. Enerion is an effective and safe drug for the treatment of asthenia in patients with psychovegetative syndrome. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2004; 12(10): 631–633 (In Russ.)). EDN: TTOWCN.

34. (Acevedo C.H., Yibirin M.G., Rochaet A. et al. Astenia en pacientes que asisten a la consulta externa: Valoracion a traves de la escala de intensidad de fatiga (FSS). Archivos Venezolanos de farmacologia e Terapeutica. 2012; 31(3): 62–66 (In Spanish)).

35. Shah S.N.; Sulbutiamine Study Group. Adjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia. J Assoc Physicians India. 2003; 51: 891–95. PMID: 14710977.

36. Левин О.С., Слизкова Ю.Б. Применение Энериона при лечении астенических расстройств у больных, перенесших легкую черепно-мозговую травму. Журнал неврологии и психиатрии им. C.C. Корсакова. 2007; 107(5): 44–48. (Levin O.S., Slizkova Yu.B. The use of Enerion in the treatment of asthenic disorders in patients after mild cranio-cerebral trauma. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2007; 107(5): 44–48 (In Russ.)). EDN: HZTDJB.

37. Sevim S., Kaleagası H., Tasdelen B. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. Mult Scler Relat Disord. 2017; 16: 40–43.

https://doi.org/10.1016/j.msard.2017.05.010. PMID: 28755683.

38. Гурак С.В., Парфенов В.А. Астения после инсульта и инфаркта миокарда и ее лечение Энерионом. Клиническая геронтология. 2005; 11(8): 9–12. (Gurak S.V., Parfenov V.A. Asthenia after stroke and myocardial infarction and its treatment with Enerion. Klinicheskaya gerontologiya = Clinical Gerontology. 2005; 11(8): 9–12 (In Russ.)). EDN: HQUTCZ.

39. Хасанова Д., Мухутдинова Э., Житкова Ю. Энерион (сульбутиамин) в лечении постинсультного астенического синдрома. Врач. 2008; (7): 66–69. (Khasanova D., Mukhutdinova E., Zhitkova Y. Enerion (sulbutiamine) in the treatment of post-stroke asthenic syndrome. Vrach = The Doctor. 2008; (7): 66–69 (In Russ.)). EDN: KXLKAP.